Alkermes plc

ALKS ·Healthcare, Drug Manufacturers - General, Ireland
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $501.0K $-66.5M $49.3M $82.8M $87.1M $22.5M $146.5M $92.4M
Depreciation & Amortization $30.3M $19.4M $3.8M $8.1M $7.8M $7.4M $6.8M $7.0M
Depreciation — — — — — — — —
Amortization $22.6M $11.7M — $0 $0 $0 $14.0K $14.0K
Stock-Based Compensation $31.1M $36.3M $26.3M $24.7M $25.0M $22.8M $20.7M $22.5M
Net Cash from Operating Activities $145.2M $-165.7M $170.1M $101.7M $150.2M $98.8M $190.4M $81.6M
Investing Activities
Capital Expenditures $8.1M $4.1M $-20.0K $17.3M $13.0M $10.1M $9.8M $8.3M
Business Acquisitions $0 $2.09B — — — — — —
Net Cash from Investing Activities $-2.4M $-2.08B $322.3M $-6.7M $-29.2M $9.1M $-13.9M $-109.3M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases $0 $27.7M — — — — — —
Net Cash from Financing Activities $17.2M $1.47B $10.9M $315.0K $405.0K $747.0K $-281.7M $-111.1M
Net Change in Cash $160.0M $-768.2M $503.3M $95.3M $121.4M $108.7M $-105.1M $-138.9M
Free Cash Flow $137.0M $-169.8M $170.1M $84.4M $137.2M $88.7M $180.6M $73.3M
← Newer Page 1 of 8 Older →